Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Syringe Pump · 1 trial · 1 indication
The VAS scale consists of a 100 mm line on a paper where 1 will be no pain and 100 being the worst pain imaginable. The VAS response will be recorded in millimetres (mm).
The VAS scale consists of a 100 mm line on a paper where 1 will be no pain and 100 being the worst pain imaginable. The VAS response will be recorded in mm.
| Arm | Type | Description |
|---|---|---|
| Pilot cohort | EXPERIMENTAL | Participants will receive subcutaneous injections and infusions of sodium chloride (NaCl) solution in varying combinations of speed and volume at different abdominal sites in a randomised sequence. A syringe pump with an attached syringe will be used for delivery of subcutaneous injections and infusions. |
| Main cohort | EXPERIMENTAL | Participants will receive subcutaneous injections and infusions of sodium chloride (NaCl) solution in varying combinations of speed and volume (that have passed safety assessment in pilot cohort) at different abdominal sites in a randomised sequence. A syringe pump with an attached syringe will be used for delivery of subcutaneous injections and infusions. |
| Name | Type | Description |
|---|---|---|
| Syringe Pump | DEVICE | Device used for delivery of subcutaneous injections and infusions of NaCl solution. |
Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Healthy male or female participants as judged by the investigato...
Syringe Pump is an investigational drug being studied in healthy participants. It is currently in Phase 1 clinical development, with a trial assessing the tolerability of injecting larger volumes (2-5 mL) subcutaneously at different rates, focusing on participant experience and acceptance.
Syringe Pump is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the stock exchange under the ticker NVO. The company is conducting a Phase 1 clinical trial to evaluate the drug's tolerability in healthy participants.
Syringe Pump is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess tolerability and participant experience with subcutaneous injections of larger volumes.
Syringe Pump is being studied in one Phase 1 clinical trial with the identifier NCT07769489. This trial, which is not yet recruiting, aims to enroll 100 healthy participants in Denmark to evaluate the tolerability of injecting larger volumes (2-5 mL) subcutaneously at different rates.
Syringe Pump is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in healthy participants to assess tolerability, but it has not yet received regulatory approval for any use.